Literature DB >> 22675797

Dabigatran: a new anticoagulant for stroke prevention in patients with atrial fibrillation.

Richard Weachter1.   

Abstract

Ischemic stroke is arguably the most feared complication of atrial fibrillation. While warfarin has been the most effective pharmacologic treatment for stroke prevention in patients with nonvalvular atrial fibrillation, several limitations have led to its underutilization. Recently, dabigatran (Pradaxa), a new oral anticoagulant with several potential advantages over warfarin (Coumadin), became available for use in the United States for prevention of stroke and systemic embolism in patient with nonvalvular atrial fibrillation.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22675797      PMCID： PMC6181744     

Source DB:  PubMed          Journal:  Mo Med        ISSN： 0026-6620


  21 in total

1.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  L Samuel Wann; Anne B Curtis; Craig T January; Kenneth A Ellenbogen; James E Lowe; N A Mark Estes; Richard L Page; Michael D Ezekowitz; David J Slotwiner; Warren M Jackman; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Jean-Yves Le Heuzey; Harry J Crijns; James E Lowe; Anne B Curtis; S Bertil Olsson; Kenneth A Ellenbogen; Eric N Prystowsky; Jonathan L Halperin; Juan Luis Tamargo; G Neal Kay; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Judith S Hochman; Christopher E Buller; Frederick G Kushner; Mark A Creager; Erik Magnus Ohman; Steven M Ettinger; William G Stevenson; Robert A Guyton; Lynn G Tarkington; Jonathan L Halperin; Clyde W Yancy
Journal:  Circulation       Date:  2010-12-20       Impact factor: 29.690

Review 2.  Dabigatran etexilate: a new oral thrombin inhibitor.

Authors:  Graeme J Hankey; John W Eikelboom
Journal:  Circulation       Date:  2011-04-05       Impact factor: 29.690

Review 3.  Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.

Authors:  Fazeel M Siddiqui; Adnan I Qureshi
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

Review 4.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

5.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

Review 6.  Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.

Authors:  Bengt I Eriksson; Daniel J Quinlan; John W Eikelboom
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

7.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

Authors:  B I Eriksson; O E Dahl; N Rosencher; A A Kurth; C N van Dijk; S P Frostick; P Kälebo; A V Christiansen; S Hantel; R Hettiarachchi; J Schnee; H R Büller
Journal:  J Thromb Haemost       Date:  2007-11       Impact factor: 5.824

8.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

9.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dietmar Gansser; Willy Roth
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.